BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Al-Kuraishy HM, Al-Gareeb AI, Alzahrani KJ, Alexiou A, Batiha GE. Niclosamide for Covid-19: bridging the gap. Mol Biol Rep 2021;48:8195-202. [PMID: 34664162 DOI: 10.1007/s11033-021-06770-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Al-Kuraishy HM, Al-Gareeb AI, Hetta HF, Alexiou A, Papadakis M, Batiha GE. Heparanase is the possible link between monkeypox and Covid-19: robust candidature in the mystic and present perspective. AMB Express 2023;13:13. [PMID: 36705773 DOI: 10.1186/s13568-023-01517-y] [Reference Citation Analysis]
2 Al-Kuraishy HM, Batiha GE, Al-Gareeb AI, Al-Harcan NAH, Welson NN. Receptor-dependent effects of sphingosine-1-phosphate (S1P) in COVID-19: the black side of the moon. Mol Cell Biochem 2023;:1-9. [PMID: 36652045 DOI: 10.1007/s11010-023-04658-7] [Reference Citation Analysis]
3 Nadwa EH, Al-Kuraishy HM, Al-Gareeb AI, Elekhnawy E, Albogami SM, Alorabi M, Batiha GE, De Waard M. Cholinergic dysfunction in COVID-19: frantic search and hoping for the best. Naunyn Schmiedebergs Arch Pharmacol 2023;396:453-68. [PMID: 36460816 DOI: 10.1007/s00210-022-02346-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Yun JS, Song H, Kim NH, Cha SY, Hwang KH, Lee JE, Jeong CH, Song SH, Kim S, Cho ES, Kim HS, Yook JI. Glycogen Synthase Kinase-3 Interaction Domain Enhances Phosphorylation of SARS-CoV-2 Nucleocapsid Protein. Mol Cells 2022;45:911-22. [PMID: 36572560 DOI: 10.14348/molcells.2022.0130] [Reference Citation Analysis]
5 Batiha GE, Al-Kuraishy HM, Al-Gareeb AI, Youssef FS, El-Sherbeni SA, Negm WA. A perspective study of the possible impact of obeticholic acid against SARS-CoV-2 infection. Inflammopharmacology 2022;:1-11. [PMID: 36484974 DOI: 10.1007/s10787-022-01111-x] [Reference Citation Analysis]
6 Pauly I, Kumar Singh A, Kumar A, Singh Y, Thareja S, Kamal MA, Verma A, Kumar P. Current Insights and Molecular Docking Studies of the Drugs under Clinical Trial as RdRp Inhibitors in COVID-19 Treatment. Curr Pharm Des 2022;28:3677-705. [PMID: 36345244 DOI: 10.2174/1381612829666221107123841] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Batiha GE, Moubarak M, Shaheen HM, Zakariya AM, Usman IM, Rauf A, Adhikari A, Dey A, Alexiou A, Hetta HF, Al-Gareeb AI, Al-Kuraishy HM. Favipiravir in SARS-CoV-2 Infection: Is it Worth it? Comb Chem High Throughput Screen 2022;25:2413-28. [PMID: 35430987 DOI: 10.2174/1386207325666220414111840] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Prathapan P. Magic bullets, magic shields, and antimicrobials in between. Pharmaceutical Science Advances 2022. [DOI: 10.1016/j.pscia.2022.100002] [Reference Citation Analysis]
9 Al-Kuraishy HM, Al-Gareeb AI, Mohammed AA, Alexiou A, Papadakis M, Batiha GE. The potential link between Covid-19 and multiple myeloma: A new saga. Immun Inflamm Dis 2022;10:e701. [PMID: 36444620 DOI: 10.1002/iid3.701] [Reference Citation Analysis]
10 Al-Kuraishy HM, Al-Gareeb AI, Albezrah NKA, Bahaa HA, El-Bouseary MM, Alexiou A, Al-Ziyadi SH, Batiha GE. Pregnancy and COVID-19: high or low risk of vertical transmission. Clin Exp Med 2022. [PMID: 36251144 DOI: 10.1007/s10238-022-00907-z] [Reference Citation Analysis]
11 Maitra S, Mukerjee N, Dey A, Ghosh A, Alexiou A. Drug Development Strategies and Immunological Aspects of SARS-CoV-2. TOPHJ 2022;15. [DOI: 10.2174/18749445-v15-e2206200] [Reference Citation Analysis]
12 Alomair BM, Al-Kuraishy HM, Al-Buhadily AK, Al-Gareeb AI, De Waard M, Elekhnawy E, Batiha GE. Is sitagliptin effective for SARS-CoV-2 infection: false or true prophecy? Inflammopharmacology 2022. [PMID: 36180664 DOI: 10.1007/s10787-022-01078-9] [Reference Citation Analysis]
13 Al-Kuraishy HM, Al-Gareeb AI, Al-Maiahy TJ, Alexiou A, Mukerjee N, Batiha GE. Prostaglandins and non-steroidal anti-inflammatory drugs in Covid-19. Biotechnol Genet Eng Rev 2022;:1-21. [PMID: 36098621 DOI: 10.1080/02648725.2022.2122290] [Reference Citation Analysis]
14 Al-Kuraishy HM, Al-Gareeb AI, Alexiou A, Mukerjee N, Al-Hamash SMJ, Al-Maiahy TJ, Batiha GE. 5-HT/CGRP pathway and Sumatriptan role in Covid-19. Biotechnol Genet Eng Rev 2022;:1-26. [PMID: 36042570 DOI: 10.1080/02648725.2022.2108996] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Babalghith AO, Al-Kuraishy HM, Al-Gareeb AI, De Waard M, Sabatier JM, Saad HM, Batiha GE. The Potential Role of Growth Differentiation Factor 15 in COVID-19: A Corollary Subjective Effect or Not? Diagnostics (Basel) 2022;12:2051. [PMID: 36140453 DOI: 10.3390/diagnostics12092051] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
16 Alkhayyat SS, Al-Kuraishy HM, Al-Gareeb AI, El-Bouseary MM, AboKamer AM, Batiha GE, Simal-Gandara J. Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail. Inflamm Res 2022. [PMID: 35941297 DOI: 10.1007/s00011-022-01615-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Al-Kuraishy HM, Al-Gareeb AI, Negm WA, Alexiou A, Batiha GE. Ursolic acid and SARS-CoV-2 infection: a new horizon and perspective. Inflammopharmacology 2022. [PMID: 35922738 DOI: 10.1007/s10787-022-01038-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Mortazavi-Jahromi SS, Aslani M. Dysregulated miRNAs network in the critical COVID-19: An important clue for uncontrolled immunothrombosis/thromboinflammation. Int Immunopharmacol 2022;110:109040. [PMID: 35839566 DOI: 10.1016/j.intimp.2022.109040] [Reference Citation Analysis]
19 El-Saber Batiha G, Al-Gareeb AI, Saad HM, Al-Kuraishy HM. COVID-19 and corticosteroids: a narrative review. Inflammopharmacology 2022. [PMID: 35562628 DOI: 10.1007/s10787-022-00987-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
20 Mostafa-Hedeab G, Al-Kuraishy HM, Al-Gareeb AI, Jeandet P, Saad HM, Batiha GE. A raising dawn of pentoxifylline in management of inflammatory disorders in Covid-19. Inflammopharmacology 2022. [PMID: 35486310 DOI: 10.1007/s10787-022-00993-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
21 Yun JS, Kim NH, Song H, Cha SY, Hwang KH, Lee JE, Jeong C, Song SH, Kim S, Cho ES, Kim HS, Yook JI. Emergence of glycogen synthase kinase-3 interaction domain enhances phosphorylation of SARS-CoV-2 nucleocapsid protein.. [DOI: 10.1101/2022.01.24.477037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Villandre J, White V, Lear TB, Chen Y, Tuncer F, Vaiz E, Tuncer B, Lockwood K, Camarco D, Liu Y, Chen BB, Evankovich J. A Repurposed Drug Screen for Compounds Regulating Aquaporin 5 Stability in Lung Epithelial Cells. Front Pharmacol 2022;13:828643. [DOI: 10.3389/fphar.2022.828643] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Al-Kuraishy HM, Al-Gareeb AI, Al-Hussaniy HA, Al-Harcan NAH, Alexiou A, Batiha GE. Neutrophil Extracellular Traps (NETs) and Covid-19: A new frontiers for therapeutic modality. Int Immunopharmacol 2022;104:108516. [PMID: 35032828 DOI: 10.1016/j.intimp.2021.108516] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 30.0] [Reference Citation Analysis]
24 黄 梅. New Use for an Old Drug of Niclosamide. HJCET 2022;12:81-87. [DOI: 10.12677/hjcet.2022.122012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]